IP Library Patent Application 13732267
Patent Application
App. No. 13/732,267

LIPOSOMAL FORMULATION FOR ORAL ADMINISTRATION OF GLUTATHIONE (REDUCED) VIA GEL CAPSULE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/732,267
Abstract

The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation in a gel cap. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.

Claims (29)

1 . A composition for oral delivery of glutathione (reduced) comprising:

a gel capsule; and

glutathione (reduced) encapsulated within the gel capsule, said glutathione (reduced) being stabilized in a liposomal pharmaceutical carrier capable of being ingested orally, and capable of delivering glutathione (reduced) in a physiologically active state to improve symptoms in disease states by transfer of the glutathione (reduced) into animal cells,

where the concentration of reduced glutathione in the entrapped aqueous space of the liposomes is at least about 123 mM.

2 . The composition of claim 1 , further comprising:

lecithin encapsulated within the gel capsule.

3 . The composition of claim 1 , further comprising:

up to 15-20% water encapsulated within the gel capsule.

4 . The composition of claim 1 , further comprising:

glycerin encapsulated within the gel capsule.

5 . The composition of claim 1 , further comprising:

sorbitan oleate encapsulated within the gel capsule.

6 . The composition of claim 1 , further comprising:

polysorbate 20 encapsulated within the gel capsule.

7 . The composition of claim 1 , further comprising:

potassium sorbate encapsulated within the gel capsule.

8 . A method of treating a disease comprising:

delivering glutathione orally via a gel capsule including reduced glutathione encapsulated in a liposomal pharmaceutical carrier within said gel capsule where the concentration of reduced glutathione in the entrapped aqueous space of the liposomes is at least about 123 mM.

9 . The method of claim 8 , where the gel capsule further includes:

lecithin encapsulated within the gel capsule.

10 . The method of claim 8 , where the gel capsule further includes:

up to 15-20% water encapsulated within the gel capsule.

11 . The method of claim 8 , where the gel capsule further includes:

sorbitan oleate encapsulated within the gel capsule.

12 . The method of claim 8 , where the gel capsule further includes:

polysorbate 20 encapsulated within the gel capsule.

13 . The method of claim 8 , where the gel capsule further includes:

potassium sorbate encapsulated within the gel capsule.

14 . The method of claim 8 , where the disease is selected from the group consisting of cystic fibrosis, liver disease, Parkinson's disease, heart attack, stroke, and diabetes.

Assignments (1)
NUNC PRO TUNC ASSIGNMENT Recorded Apr 19, 2013
From: GUILFORD, FREDERICK TIMOTHY; KELLER, BRIAN CHARLES
To: YOUR ENERGY SYSTEMS, LLC
Reel/Frame 030252/0960 →